CCHF in Pregnancy Carries Separate Risks for Mother and Fetus Across Gestation
Crimean-Congo hemorrhagic fever during pregnancy remains one of the clearest examples of how an acute viral hemorrhagic infection can destabilize two patients at once. In this patient-level meta-analysis, 55 pregnancies linked to Crimean-Congo hemorrhagic fever revealed maternal mortality of 28.8% and fetal loss in 57.4% of cases, a pattern that makes the obstetric setting clinically unforgiving from the first trimester through delivery.
The numbers are not merely severe; they differ by gestational age in a way that should shape bedside judgment. Maternal mortality increased as pregnancy advanced, reaching 31.3% in the third trimester, while fetal loss peaked early, at 85.7% in the first trimester. In practical terms, the fetus is most vulnerable to early gestational infection, while the mother appears to face growing danger later in pregnancy, when blood volume, coagulation balance, and placental demands are already under strain.
Crimean-Congo hemorrhagic fever is transmitted mainly by infected Hyalomma ticks, but infection can also follow contact with viremic livestock or, less commonly, healthcare exposure. The illness usually begins with a nonspecific febrile syndrome before progressing in some patients to hemorrhage and multiorgan failure. Pregnancy adds a second layer of biological fragility because of immune modulation, altered hemostasis, and the presence of the fetoplacental unit, all of which can magnify the impact of a rapidly replicating hemorrhagic virus.
Patient-Level Synthesis From Endemic Regions
Investigators pooled published and unpublished cases from endemic settings and harmonized clinical, laboratory, obstetric, treatment, and outcome data at the individual-patient level. The final dataset included 55 pregnancies drawn from Eastern Europe, the Middle East, and Africa. Turkey contributed the largest share of reported cases at 43.6% (24/55), followed by Iran at 18.2% (10/55) and Russia at 14.5% (8/55).
Among the 37 cases with maternal age available, the median age was 26 years. Gestational age at infection was reported for 40 cases, with a median of 21 weeks, spanning first-, second-, and third-trimester infections. Tick exposure was documented in 20 of 30 cases, a reminder that the epidemiology still tracks closely with rural and vector-associated exposure patterns in endemic regions.
The analysis did not rely on aggregate case summaries alone. It integrated unpublished cases from Turkey and Russia alongside the published literature, which strengthens the signal around outcome patterns in a disease where randomized data are absent and pregnant patients are routinely excluded from antiviral studies. The resulting cohort is still small, but it is larger and more clinically coherent than isolated case reports, and that matters when the question is whether gestational age changes risk.
Maternal Death and Fetal Loss Diverge by Trimester
Across the full cohort, maternal mortality reached 15 deaths among 52 cases with known maternal outcome, while fetal loss occurred in 31 of 54 cases with known fetal outcome. Those outcome rates are not symmetrical, and the asymmetry is clinically important. Fetal loss was highest in the first trimester, which fits with the biologic vulnerability of early placentation and embryonic development. Maternal mortality, by contrast, climbed with advancing gestation, reaching its highest observed proportion in the third trimester.
The report also examined treatment signals. Ribavirin use during the third trimester was associated with a lower observed maternal mortality rate, with an odds ratio of 0.33, 95% CI 0.13–0.84, and p = 0.031. Because these were not randomized data, that association cannot be treated as proof of benefit, but it does align with the biologic premise that early viral suppression may blunt the downstream cascade of endothelial injury, hemorrhage, and organ dysfunction.
By the time overt bleeding develops, the window for rescue may already be narrowing.
Why Pregnancy Changes the Risk Curve
The pathophysiology of severe CCHF makes pregnancy a particularly dangerous context. CCHF can drive endothelial dysfunction, thrombocytopenia, coagulation derangement, and widespread inflammatory injury. Pregnancy already shifts hemostatic balance toward a procoagulant state, yet hemorrhagic fever can overwhelm that balance in the opposite direction, producing massive bleeding and disseminated intravascular coagulation. For the fetus, placental infection or placental dysfunction can end the pregnancy before maternal illness fully declares itself.
That dual vulnerability explains why obstetric complications in the literature have included spontaneous abortion, intrauterine fetal demise, preterm delivery, and neonatal death. Vertical transmission has also been reported, which broadens concern beyond the pregnancy itself and into neonatal surveillance and postnatal infection control.
What the Evidence Can and Cannot Support
The study’s design is its strength and its constraint. Patient-level synthesis offers more usable clinical detail than scattered case reports, but the evidence base still consists largely of heterogeneous reports with variable completeness. Missing data were handled by available-case analysis rather than imputation, and the investigators explicitly note the limits imposed by selective reporting and the lack of comparator groups. Formal risk-of-bias tools were not applicable in most included studies because the underlying literature consisted mainly of case reports and small case series.
Even with those limitations, the clinical direction is hard to ignore. Pregnancy-specific management of CCHF remains insufficiently standardized, and the findings argue for earlier recognition, careful trimester-aware risk assessment, and more deliberate surveillance in endemic regions. The dataset also supports a practical research agenda: larger multicenter registries, standardized obstetric outcome reporting, and prospective capture of maternal severity markers and neonatal outcomes.
For clinicians in endemic or travel-linked settings, the message is direct. A febrile pregnant patient with tick exposure, compatible hemorrhagic symptoms, or unexplained obstetric deterioration should trigger urgent evaluation for CCHF, because the cost of delayed diagnosis is measured not only in maternal survival but in fetal viability as well.
The unanswered questions are still substantial: which maternal laboratory features best predict deterioration, how much antiviral timing changes outcomes, and whether standardized protocols can shift fetal loss rates in the earliest gestational infections.